Prognose
Analytikernes gennemsnitlige kursmål er 121,03 € (+108,64 %). Medianen er 136,70 € (+135,65 %).
| Køb |
14 |
| Behold |
9 |
| Sælg |
3 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Corcept Therapeutics raises guidance after strong quarter and record volume
Corcept reports a massive jump in profit and an increase in revenue on record trading volume, prompting management to sharply raise its full-year forecast. The new oncology drug Lifyorli is expected to deliver further growth in the medium term. Management is targeting annual sales of up to $5 billion by 2030. » Mere på finanzen.net
Corcept Therapeutics reaches new all-time high after strong quarterly results
The stock of Corcept Therapeutics rose to an all-time high of $122.50 and is currently trading at $121.31, corresponding to a market capitalization of $13.13 billion. In the second quarter of 2026 the company reported revenue of $256.1 million (+32% year-on-year) and raised its full-year guidance to $1.1–1.2 billion. Analysts responded with price-target increases and positive assessments, while InvestingPro currently rates the stock as overvalued relative to its fair value. » Mere på de.investing.com
Corcept Therapeutics reaches 52-week high at $95.18
Shares of Corcept Therapeutics rose to a 52-week high of $95.18, gaining 152% over the past six months and 163% year-to-date. The company has resubmitted the New-Drug-Application for Relacorilant to the FDA for the treatment of Cushing’s syndrome; the review is expected to take six months. At ASCO, Corcept presented data from the phase‑3 ROSELLA study showing a 35% reduction in risk of death with Lifyorli (Relacorilant) plus nab‑paclitaxel. First-quarter 2026 revenues of about $165 million were below consensus, but analysts still raised price targets and reiterated buy ratings. » Mere på de.investing.com
Corcept resubmits approval application for relacorilant to treat Cushing's syndrome to FDA
Corcept resubmitted the New Drug Application for relacorilant to the FDA and included additional analyses of the originally requested data. The company expects a six-month review period; the submission is based on data from the GRACE study, the phase III GRADIENT study, a long-term extension and earlier development phases. According to Corcept, relacorilant improves symptoms of Cushing's syndrome without certain side effects, received orphan-drug status and is also already FDA-approved as Lifyorli for platinum-resistant ovarian cancer. Investors reacted positively; the stock is up about 141% year-to-date and the company has a market capitalization of $8.79 billion. » Mere på de.investing.com
Corcept shows phase‑3 data: relacorilant plus nab‑paclitaxel extends survival in ovarian cancer
In the ROSELLA trial, relacorilant (Lifyorli) in combination with nab‑paclitaxel reduced the risk of death by 35% versus nab‑paclitaxel alone (hazard ratio 0.65; p=0.0004) and increased median overall survival to 16.0 versus 11.9 months. A biomarker test was not required; subgroups with a short taxane‑free interval showed similar effects. Lifyorli was approved by the FDA in March 2026 for the combination therapy in platinum‑resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. The stock is up 96% so far in 2026 (week +13.6%); frequent adverse events and 35% serious adverse events in the combination group were reported. » Mere på de.investing.com
Historisk udbytte Udbytte
Alle nøgletal for udbytte Alle nøgletalI 2022 har Corcept Therapeutics allerede udloddet 0,26 € i udbytte. Den seneste udlodning fandt sted i marts 2022.
Virksomhedstal
I det seneste kvartal havde Corcept Therapeutics en omsætning på 300,59 mio. € og et nettoresultat på 111,93 mio. €
| (EUR) | september 2026 | YoY |
|---|---|---|
| Omsætning | 300,59 mio. | 69,89 % |
| Bruttofortjeneste | 296,52 mio. | 71,38 % |
| Nettoresultat | 111,93 mio. | 567,83 % |
| EBITDA | 107,12 mio. | 699,66 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 6,76 mia. € |
Antal aktier | 109,44 mio. |
Højeste/laveste i 52 uger | 115,18 € - 26,12 € |
| Udbytte | Nej |
Beta | 0,45 |
P/E (PE Ratio) | 45,19 |
PEG (PEG Ratio) | 0,90 |
K/I (PB Ratio) | 8,67 |
P/S (PS Ratio) | 7,70 |
Virksomhedsprofil
Corcept Therapeutics Incorporated opdager, udvikler og kommercialiserer lægemidler til behandling af alvorlige metaboliske, onkologiske og neuropsykiatriske lidelser i USA. Virksomheden tilbyder Korlym (mifepriston)-tabletter som et oral lægemiddel, der tages én gang dagligt, til behandling af hyperglykæmi sekundær til hyperkortisolisme hos voksne patienter med endogent Cushings syndrom, som har type 2-diabetes mellitus eller glukoseintolerance, og som enten har fejlet kirurgi eller ikke er kandidater til kirurgi. Virksomheden udvikler relacorilant til behandling af patienter med Cushings syndrom; og nab-paclitaxel i kombination med relacorilant, som har gennemført et fase II-klinisk forsøg til behandling af patienter med avancerede ovarietumorer, samt til behandling af kortisoloverskud. Virksomheden udvikler desuden selektiv kortisolmodulator til behandling af patienter med metastatisk kastrationsresistent prostatacancer; selektiv kortisolmodulator til behandling af antipsykotika-induceret vægtøgning og andre lidelser; samt FKBP5-genekspressionsanalyser. Corcept Therapeutics Incorporated blev stiftet i 1998 og har hovedkvarter i Menlo Park, Californien.
| Navn | Corcept Therapeutics |
| CEO | Joseph K. Belanoff |
| Hjemsted | Redwood City,
ca USA |
| Websted | |
| Sektor | Sundhed |
| Branche | Lægemidler |
| Børsnotering | 14.04.2004 |
| Medarbejdere | 730 |
Tickersymboler
| Børs | Symbol |
|---|---|
NASDAQ | CORT |
London Stock Exchange | 0I3Q.L |
Frankfurt | HTD.F |
Düsseldorf | HTD.DU |
London | 0I3Q.L |
SIX | HTD.SW |
München | HTD.MU |
Milan | 1CORT.MI |